AMG TimesSquare Mid Cap Growth Fund
TMDIX
NASDAQ- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- AMG TimesSquare Mid Cap Growth Fund (TMDIX) is an open-end mutual fund managed by Affiliated Managers Group, Inc. (AMG Funds) in partnership with TimesSquare Capital Management, LLC, focusing on long-term capital appreciation through investments primarily in equity securities of mid-cap growth companies. The fund invests at least 80% of its net assets in common stocks of companies whose market capitalization falls within the range of the Russell Midcap Growth Index at the time of purchase; it employs a bottom-up, fundamental research process targeting high-quality companies with sustainable competitive advantages, strong management teams, and attractive growth prospects across sectors such as technology, healthcare, consumer discretionary, and industrials. Share classes include Investor (TMDIX), Institutional (TMDYX), and others, with services encompassing daily liquidity, professional portfolio management, and risk controls like diversification and position sizing limits. The fund operates globally but maintains a primary focus on U.S.-domiciled mid-cap growth stocks, with selective international exposure; it was launched in 2004 and is headquartered in New York alongside TimesSquare Capital Management, a subsidiary-like affiliate of AMG based in the United States. Target investors include individual and institutional clients seeking growth-oriented exposure with mid-cap risk-return profiles. AMG Funds serves as the distributor and overall sponsor, leveraging TimesSquare's specialized research team for security selection. In recent developments, the fund benefited from AMG's strategic enhancements in 2024-2025, including expanded distribution partnerships and technology integrations for improved analytics, amid a broader industry shift toward active mid-cap strategies following market volatility; no major acquisitions or name changes occurred, but performance attribution analysis highlighted strengthened positions in AI-driven tech and biotech subsectors during 2025's equity rally.